Allogeneic immune response

The allogeneic immune response is a complex physiological process where the host's immune system recognizes and attacks non-self antigens, known as alloantigens, found on tissues or organs transplanted from another individual of the same species (Ingulli, 2010). This response is primarily driven by the recognition of foreign Major Histocompatibility Complex (MHC) molecules by recipient T-cells through direct, indirect, or semi-direct pathways of allorecognition (Nature Reviews Immunology, 2013). Once activated, these T-cells orchestrate a cascade of events including the recruitment of macrophages, the production of inflammatory cytokines, and the activation of B-cells to produce donor-specific antibodies, ultimately leading to graft injury or rejection. In hematopoietic stem cell transplantation, this process can also occur in reverse, known as graft-versus-host disease (GVHD), where donor immune cells attack recipient tissues (NIH, 2022). Therapeutic management of the allogeneic response relies on potent immunosuppressive drugs that target specific molecular checkpoints, such as calcineurin, mTOR, or costimulatory pathways, to prevent graft loss. While essential for transplant success, these therapies require careful monitoring due to the significant risks of systemic immunosuppression, including life-threatening infections and increased cancer susceptibility.

Other names

Alloimmune responseAlloreactivityGraft rejection responseHost-versus-graft responseGraft-versus-host responseAlloantigen recognition

Inhibition of T-lymphocyte activation and proliferation, blockade of costimulatory signals (e.g., CD80/86-CD28), inhibition of cytokine synthesis (e.g., IL-2), and depletion of reactive immune cell populations (StatPearls, 2023).